Compare RNP & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNP | EVO |
|---|---|---|
| Founded | 2003 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | RNP | EVO |
|---|---|---|
| Price | $21.07 | $3.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 76.1K | 47.1K |
| Earning Date | 01-01-0001 | 04-08-2026 |
| Dividend Yield | ★ 7.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | N/A | $10.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.27 | $2.31 |
| 52 Week High | $22.99 | $4.42 |
| Indicator | RNP | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 57.12 | 56.03 |
| Support Level | $20.44 | $2.88 |
| Resistance Level | $21.24 | $3.75 |
| Average True Range (ATR) | 0.28 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 62.10 | 89.58 |
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances. The Fund seeks to achieve its objectives through a portfolio of income producing common stock issued by REITs and preferred and other debt securities.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.